| 000 | 00882 a2200229 4500 | ||
|---|---|---|---|
| 005 | 20250517155855.0 | ||
| 264 | 0 | _c20181012 | |
| 008 | 201810s 0 0 eng d | ||
| 022 | _a1538-7836 | ||
| 024 | 7 |
_a10.1111/jth.13750 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTripodi, A | |
| 245 | 0 | 0 |
_aThe recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran: comment. _h[electronic resource] |
| 260 |
_bJournal of thrombosis and haemostasis : JTH _c09 2017 |
||
| 300 |
_a1882-1883 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aAntithrombins |
| 650 | 0 | 4 | _aDabigatran |
| 773 | 0 |
_tJournal of thrombosis and haemostasis : JTH _gvol. 15 _gno. 9 _gp. 1882-1883 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/jth.13750 _zAvailable from publisher's website |
| 999 |
_c27249802 _d27249802 |
||